PI3K inhibition to overcome endocrine resistance in breast cancer.

about

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

P2860

Q57280932-D04CC591-9474-45A7-8769-8EC0DEC5F42E

P2860

PI3K inhibition to overcome endocrine resistance in breast cancer.

Item

http://www.wikidata.org/entity/Q47776273

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

PI3K inhibition to overcome endocrine resistance in breast cancer.

@en

PI3K inhibition to overcome endocrine resistance in breast cancer.

@nl

type

Item

label

PI3K inhibition to overcome endocrine resistance in breast cancer.

@en

PI3K inhibition to overcome endocrine resistance in breast cancer.

@nl

prefLabel

PI3K inhibition to overcome endocrine resistance in breast cancer.

@en

PI3K inhibition to overcome endocrine resistance in breast cancer.

@nl

P1476

PI3K inhibition to overcome endocrine resistance in breast cancer.

@en

P2093

Bryan T Hennessy

http://www.w3.org/2001/XMLSchema#string

Jack P Gleeson

http://www.w3.org/2001/XMLSchema#string

Niamh M Keegan

http://www.w3.org/2001/XMLSchema#string

Patrick G Morris

http://www.w3.org/2001/XMLSchema#string

P2860

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

Comprehensive molecular portraits of human breast tumours

The PI3K pathway as drug target in human cancer

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

P304

1-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/13543784.2018.1417384

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29252036

http://www.w3.org/2001/XMLSchema#string

PI3K inhibition to overcome endocrine resistance in breast cancer.

about

P2860

P2860

PI3K inhibition to overcome endocrine resistance in breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698